Walgreens: Don’t call us just a retailer

Amy Baxter | | Health Exec | Policy & Regulations
track

With CVS Health on the brink of acquiring health insurer Aetna, Walgreens wants to revamp its image as more than a retailer, according to a report by CNBC.

After the closure of the CVS-Aetna deal, Walgreens will still “be largely a pharmacy chain, though the company is trying to change that,” CNBC reported. Those changes include several recent partnerships with healthcare companies such as Humana and LabCorp, a diagnostics company.

The new direction will test some health services in Walgreens stores and underscores how Walgreens may be trying to keep up with its main competitor amid a consolidating marketplace.

"So you will see that in a few years our stores will be completely different and will give lot of prominence, even in front of stores, to health and beauty," Walgreens Boots Alliance CEO Stefano Pessina told CNBC.

See the full story below:

Walgreens wants to be seen as a health-care company, not just a retailer

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.